RCAN2

Across TCGA pan-cancer cohorts, RCAN2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RCAN2 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RCAN2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RCAN2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, SKCM, and ESCA are the cancer types where RCAN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.091	0.555	.001	18	view →
SKCM	DFS	Median	III,IV	1.000	0.238	.009	8	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
SARC	DFS	Median	All	0.109	0.632	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RCAN2–LIHC (DFS)

Open the LIHC breakdown →